NT5C2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL23124	0.85	2/20
SCHEMBL29514799	0.85	2/20
SCHEMBL8381776	0.83	2/20
SCHEMBL6463477	0.79	2/20
SCHEMBL23683051	0.71	2/20
SCHEMBL16619108	0.69	2/20
SCHEMBL9230081	0.68	2/20
SCHEMBL16618808	0.67	2/20
SCHEMBL3038563	0.63	2/20
SCHEMBL10644711	0.62	2/20
SCHEMBL22118772	0.62	2/20
SCHEMBL38666421	0.60	2/20
SCHEMBL1898392	0.59	2/20
SCHEMBL5694052	0.58	2/20
SCHEMBL7264355	0.58	2/20
SCHEMBL8121393	0.58	2/20
SCHEMBL6933558	0.58	2/20
SCHEMBL30536136	0.58	2/20
SCHEMBL475842	0.57	2/20
SCHEMBL5694204	0.57	2/20

Clinical trials — most relevant to NT5C2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Preventing Acute Kidney Injury (AKI) in Pediatric Patients	PHASE3	UNKNOWN
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension	PHASE3	COMPLETED
University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial	PHASE1/PHASE2	COMPLETED
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)	PHASE1/PHASE2	RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer	PHASE2	RECRUITING
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	PHASE1/PHASE2	COMPLETED
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Nucleoside Therapy in Patients With Telomere Biology Disorders	PHASE1	RECRUITING
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients	EARLY_PHASE1	RECRUITING
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia	nan	COMPLETED
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart	nan	UNKNOWN
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Caffeine Efficacy in ADCY5-related Dyskinesia	nan	UNKNOWN
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)	nan	UNKNOWN
Genetics of Neonatal Encephalopathy and Related Disorders	nan	RECRUITING
A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates	nan	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Blood Sample Donations to Study the Role of Genes in Pain	nan	COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E	nan	UNKNOWN
Polymorphisms, Caffeine and Sleep Disorders	nan	COMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Epigenetics, DNA Methylation Patterns and Periodontal Disease	nan	COMPLETED
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a NT5C2 binder may also engage these)

Protein	Name	Similarity
Q3V1L4	—	1.000	Q3V1L4 →
D3ZMY7	—	1.000	D3ZMY7 →
Q5RA22	—	1.000	Q5RA22 →
O46411	—	1.000	O46411 →
Q5ZIZ4	—	0.997	Q5ZIZ4 →
Q5EBF1	—	0.991	Q5EBF1 →
Q6DKB0	—	0.990	Q6DKB0 →
P98200	—	0.942	P98200 →
KCNT2	Potassium channel subfamily T member 2	0.941	landscape →
C7EXK4	—	0.939	C7EXK4 →
GNPDA1	Glucosamine-6-phosphate deaminase 1	0.936	landscape →
D3Z649	—	0.936	D3Z649 →
E1C6Q1	—	0.936	E1C6Q1 →
P70704	—	0.935	P70704 →
Q9DFS6	—	0.934	Q9DFS6 →
Q6UVM4	—	0.934	Q6UVM4 →
Q9NTI2	—	0.932	Q9NTI2 →
P48454	—	0.931	P48454 →
P20651	—	0.930	P20651 →
NT5C3B	7-methylguanosine phosphate-specific 5'-nucleotidase	0.930	landscape →
Q9HB90	—	0.930	Q9HB90 →
F1QH17	—	0.929	F1QH17 →
A0A1S4A695	—	0.928	A0A1S4A695 →
D3Z7P3	—	0.928	D3Z7P3 →
Q9NQL2	—	0.928	Q9NQL2 →
Q1W376	—	0.928	Q1W376 →
Q5R8T8	—	0.927	Q5R8T8 →
Q1W377	—	0.927	Q1W377 →
Q7RTP6	—	0.927	Q7RTP6 →
Q91YD4	—	0.927	Q91YD4 →